Struggling Arena Pharma axes 80 jobs, narrows R&D

Just a couple of weeks after booting company co-founder and CEO Jack Lief out of the company, a struggling Arena Pharmaceuticals ($ARNA) has followed up with a move to ax 35% of its staff--some 80 jobs--while narrowing its R&D focus. Arena has been losing market share with its obesity drug Belviq, which has proved to be a troublesome therapy to market. The focus at Arena now will be on "near-term" activities. Company shares are down 8% this morning. More cuts are also on the way. Release

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera